# Pizarra — PT-pseudo_4d54f04e26ae (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4d54f04e26ae
Task: 1

Encounter: Urology - outpatient on 17 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 34.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.352 ng/mL²
  - PSA velocity: 0.68 ng/mL/yr
  - Prior PSA: 29.7 ng/mL
  - Prostate volume: 99.5 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.739 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis
  - Problem list / PMHx: Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 34.7 ng/mL. PI-RADS 4. PSAD 0.35. Prostate volume 100 mL. DRE nodus. csPCa 0.74.

Vitals: weight 69 kg, height 174 cm, BMI 22.8, BP 108/83 mmHg, HR 67 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2007).

Chief complaint: Sustained PSA elevation alongside a Negative prior biopsy defines the current clinical presentation.

History: A sixty-six-year-old ICT consultant, never married but residing with his partner, first entered clinical evaluation in early 2023 due to an incidental PSA spike. Chronic mild lower urinary tract complaints persist, currently registering a 4 on the IPSS scale, while osteoarthritis is managed solely with paracetamol on an as-needed basis. Tobacco use ceased in 2007 following a cumulative 13 pack-year exposure; leisure activities now feature weekend hiking alongside his partner, accompanied by moderate alcohol intake averaging three units per week. Recent outpatient assessments covered routine thyroid function screening and an ophthalmology consultation for early cataract development, both demonstrating stability. Geographic distance places his residence over ninety minutes from the medical center, prompting a specific preference for remote telephone consultations during subsequent care phases.

Physical examination: DRE — prostate texture: asymmetrically hypertrophied with a distinct, firm nodule localized to the right mid-gland. General assessment remains within normal limits, displaying unremarkable cardiopulmonary findings and stable resting vital parameters.

Patient info: ICT consultant; Never married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 3 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Ophthalmology — cataract review.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.56 +/- 0.21   (95% CI 0.14-0.92)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 4.0 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=34.7, age=66.0, psad=0.352, dre_ord=1.0, vol=99.5, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS 4, PSA 34.7, prior negative biopsy, etc.). It could not account for the PSA velocity (0.68 ng/mL/yr), the specific PSA density (0.352 ng/mL²), or the specific prostate volume (99.5 mL), which are crucial for risk stratification.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a wide uncertainty interval (0.56 +/- 0.21), indicating the classifier is highly uncertain. This uncertainty could be due to the panel containing conflicting signals: a high csPCa probability (0.739) against a negative prior biopsy, or the PI-RADS 4 score being insufficient on its own without context from the MRI prose or PSA trajectory.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology / mpMRI report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context on the sustained PSA elevation and LUTS
laboratory panel - full panel
family-history anamnesis
Retrieving the radiology report is critical to determine if the PI-RADS 4 lesion is stable or evolving, which directly impacts the decision to re-biopsy.

GUIDELINE ANCHOR
The guideline suggests repeating biopsy after a negative biopsy when the mpMRI shows a PI-RADS 4-5 lesion, but the decision depends on risk factors like PSA density.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division, UMCG Groningen – 10 February 2025 | Modality: Prostate mpMRI
The report describes a PI-RADS 4 lesion in the right mid-gland peripheral zone, measuring approximately 14 x 11 x 10 mm, with pronounced diffusion restriction. It notes capsular margins remain intact without extracapsular spread or suspicious nodal enlargement.

get_psa_trend
The PSA trend shows a significant rise from 5.0 ng/mL in Feb 2023 to 34.7 ng/mL in Feb 2025, indicating a rising trajectory.

get_previous_notes
The previous notes document a negative systematic sampling in early 2024, followed by a sustained elevation to 29.5 ng/mL, prompting a referral for comprehensive evaluation, and a subsequent arrangement to evaluate MRI findings.

get_lab_results
The lab results show a current PSA of 34.7 ng/mL and a %Free PSA of 23%. Renal function (eGFR >60 mL/min/1.73m2) and other markers are within normal limits.

NOT RETRIEVED
The family-history anamnesis was not retrieved, but it is not deemed critical for the immediate decision based on the retrieved evidence.

WHAT THE EVIDENCE SUPPORTS
Findings that argue FOR sampling this patient now:
- mpMRI report: PI-RADS 4 lesion in the right mid-gland peripheral zone.
- PSA trend: Significant rising trajectory from 5.0 ng/mL to 34.7 ng/mL.
- Previous notes: Sustained PSA elevation following a prior negative biopsy.

Findings that argue AGAINST sampling this patient now:
- mpMRI report: Capsular margins remain intact without extracapsular spread or suspicious nodal enlargement.

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy due to the combination of a PI-RADS 4 lesion and a significant, rising PSA trajectory following a prior negative biopsy, aligning with the expert protocol criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

No frozen image embeddings are on file for this patient, so the image-embedding head could not be run. This contributes NO evidence in either direction — do not read the absence of a score as reassurance.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The guideline criterion strongly supports a repeat biopsy given the PI-RADS 4 lesion and prior negative biopsy. This decision is driven by the significant rising PSA trajectory from 5.0 ng/mL to 34.7 ng/mL and the PI-RADS 4 score. The evidence converged because the retrieved PSA trend and MRI report findings directly align with the protocol, overturning the statistical prior's uncertainty.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
